EGFR and hepatocellular carcinoma: A recent study investigated the association between LXRs and RALBP1 in HCC progression, in which they found that TO901317 activated LXRα upregulation of the expression levels of RALBP1 associated Eps Domain Containing 2 (REPS2) which shatters the AKT/NF-κB and MAPK pathways by EGFR inhibition in HCC cells (He et al., 2023).